Product logins

Find logins to all Clarivate products below.


Swarali Tadwalkar

Principal Consultant

Swarali has over 9 years of experience in providing consultancy support for the design and implementation of market sizing, epidemiology and real-world studies. Swarali has led multiple projects across a wide array of therapy areas, including rare diseases, oncology, and metabolic disorders. Swarali acts as a project lead/manager for projects involving data collation, epidemiology analysis, market sizing strategies, data forecasting and deriving insights from various real-world data assets. She supports clients in various aspects, such as developing strategies to understand disease market, meeting preparation and development of evidence dossiers/briefing books for FDA/EMA submissions. Throughout her career, she has developed a strong interest in tackling data challenges for analyzing complex disease indications and deriving robust insights especially for rare diseases.

Swarali has presented epidemiology forecasts and results from real-world data studies at various conferences, including, the World Cancer Congress and the Indian Cancer Congress. She holds an MPH degree from the University of South Florida, Tampa specializing in Epidemiology and Biostatistics and a BE in Biotechnology from the University of Mumbai.

Related resources

支付方愿意为便利性买单的市场准入“最佳切入点” 支付方愿意为便利性买单的市场准入“最佳切入点”
Blog June 3, 2026
支付方愿意为便利性买单的市场准入“最佳切入点”
医疗保险 定价 市场准入 真实世界数据 美国市场 药政法规
2026 年值得关注的 5 大医疗技术趋势 2026 年值得关注的 5 大医疗技术趋势
Blog May 28, 2026
2026 年值得关注的 5 大医疗技术趋势
AI/机器学习 GLP-1 医疗技术 带量采购(VBP) 日间手术中心(ASC)
《2026年最值得关注的药物》问答:礼来的下一代减肥药 《2026年最值得关注的药物》问答:礼来的下一代减肥药
Blog March 26, 2026
《2026年最值得关注的药物》问答:礼来的下一代减肥药
GLP-1 最值得关注的药物
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇 为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
Blog March 2, 2026
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
AI/机器学习 GLP-1 临床试验 交易 药政法规 衰老生物学